Analysis Pharmacovigilance

EMA keeps famciclovir authorisations unchanged after PSUSA; what 'maintenance' means for PV teams

A PSUSA concluding with 'maintenance' is a quiet outcome, but alongside CMV immunoglobulin and other 19 November safety news it shows where PV workload is really heading.

VigiEye editorial · Fri 20 Nov 2026

What happened

On 19 November 2026 the EMA published the outcome of the periodic safety update report single assessment (PSUSA) for famciclovir. The regulatory result is 'maintenance' for nationally authorised products. The EMA notice summarised in our records gives no further detail, so any finding that sits behind the outcome is not yet known from this source.

The same day, the agency published a second PSUSA outcome, for cytomegalovirus immunoglobulin, also recorded as maintenance, with the marketing authorisations to be maintained. Two maintenance outcomes in one day is not a trend, but together they are a useful reminder of what the PSUSA system mostly delivers: confirmation that the benefit-risk balance of established products remains unchanged.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →